Jpmorgan Chase & CO Phathom Pharmaceuticals, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PHAT
# of Institutions
125Shares Held
59MCall Options Held
467KPut Options Held
34.9K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$191 Million6.14% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$141 Million28.04% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$66.2 Million4.3% of portfolio
-
Invesco Ltd. Atlanta, GA3.14MShares$59.5 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.93MShares$55.4 Million0.0% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $742M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...